Prime Only Members-Only Article

President Plays Pitchman For Another Experimental COVID ‘Cure’

This Week in the Swamp: A weekly dive into the muck of the Trump administration.
TARRYTOWN, NEW YORK, UNITED STATES - 2020/10/02: View of Corporate and Research and Development Headquarters of Regeneron Pharmaceuticals, Inc. on Old Saw Mill River Road. As President Donald Trump contracted COVID-19 he has been administered a dose of experimental Regeneron treatment, according to a memorandum from the President's physician. According to company press release antibody cocktail REGN-COV2 showing it reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. (Photo by Lev Radin/Pacific Press/LightRocket via Getty Images)
TARRYTOWN, NEW YORK, UNITED STATES - 2020/10/02: View of Corporate and Research and Development Headquarters of Regeneron Pharmaceuticals, Inc. on Old Saw Mill River Road. As President Donald Trump contracted COVID-1... TARRYTOWN, NEW YORK, UNITED STATES - 2020/10/02: View of Corporate and Research and Development Headquarters of Regeneron Pharmaceuticals, Inc. on Old Saw Mill River Road. As President Donald Trump contracted COVID-19 he has been administered a dose of experimental Regeneron treatment, according to a memorandum from the President's physician. According to company press release antibody cocktail REGN-COV2 showing it reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. (Photo by Lev Radin/Pacific Press/LightRocket via Getty Images) MORE LESS
|
October 8, 2020 6:07 p.m.

Something just… doesn’t smell right about the President’s use, and subsequent pitch campaign, for a fairly new and experimental COVID-19 therapy. 

Prime Only Members-Only Article
To access exclusive analysis and reporting from TPM’s award-winning staff along with:
The Hive Member Forum
Members-Only Newsletter
Exclusive RSS Feeds
Commenting
View All Options
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Senior Editor:
Special Projects Editor:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front-End Developer:
Senior Designer:
SPECIAL DEAL FOR PAST TPM MEMBERS
40% OFF AN ANNUAL PRIME MEMBERSHIP
REJOIN FOR JUST $30